Zoetis Inc. has received Health Canada approval for Portela™ (relfovetmab injection), a new monoclonal antibody therapy designed to alleviate pain associated with osteoarthritis in cats. Portela provides three months of pain relief with a single injection and targets nerve growth factor (NGF), a key contributor to osteoarthritis pain and inflammation. The approval follows a nine-month field trial in Europe, where Portela demonstrated effectiveness and was well tolerated, including in cats with early-stage kidney disease. Zoetis plans to make Portela commercially available in Canada and the European Union in 2026.